Shots:

• The CHMP’s recommendation is based on P-III True North study evaluating Zeposia as an induction and maintenance therapy vs PBO in adult patients with moderately to severely active UC
• The study demonstrated improvements across all 1EPs and 2EPs including clinical remission- clinical response- endoscopic improvement and endoscopic histologic mucosal improvement @10 & 52wks.
• If approved by the EC- Zeposia will become the first and only oral sphingosine 1-phosphate (S1P) receptor modulator approved for UC in the EU

to­ | Ref: BMS | Image: BMS